Evidence map›Paper›PMID 29416742›Full record

ArticleOncotarget2018

MicroRNA-19a acts as a prognostic marker and promotes prostate cancer progression via inhibiting VPS37A expression.

Fangqiu Fu, Xuechao Wan, Dan Wang, Zhe Kong, Yalong Zhang, Wenhua Huang, Chenji Wang, Hai Wu, Yao Li

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Stratification of diabetic kidney diseasesFrontiers in endocrinology · 2022
    Article
  4. Review
  5. Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Fangqiu Fu *Obstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Xuechao Wan *Obstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Dan WangObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Zhe KongObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Yalong ZhangObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Wenhua HuangObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Chenji WangObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Hai WuObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Yao LiObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, PR China.
Fudan University · CNState Key Laboratory of Genetic Engineering

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is a leading cause of cancer-related deaths among males worldwide. However, the molecular mechanisms underlying the progression of PCa remain unclear. Despite several reported miRNAs in prostate cancer, these reports lacked system-level identification of differentially expressed miRNAs in large sample size. Moreover, it's still largely unknown how miRNAs result in tumorigenesis and progression of PCa. Therefore, by analyzing three public databases, we identified 16 upregulated miRNAs and 13 downregulated miRNAs, and validated miR-19a was one of the most upregulated miRNAs using qRT-PCR. The dual-luciferase reporter assays indicated VPS37A was a potential target of miR-19a. Functional assays revealed miR-19a served as an oncogene by inhibiting VPS37A. Notably, a significant inverse correlation of miR-19a and VPS37A expression was observed in PCa specimens. Moreover, miR-19a-high and VPS37A-low phenotypes were associated with poor prognosis with biochemical recurrence-free probability. In this study, we confirmed the oncogenic role of miR-19a via targeting VPS37A in PCa, identifying miR-19a and VPS37A as diagnosis and therapeutic biomarkers for PCa.

Indexed as

microRNA-19aprognostic markerprostate cancertumor progressionVPS37A

Identifiers

PMID29416742
PMCPMC5788610
OpenAlexW2774058902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.